The Prevalence of Liver Metastasis and Cancer Death to the HCC patient under treatment at the Bertoua Regional Hospital in Est Region Cameroon

Introduction: Effective therapies for hepatocellular carcinoma (HCC) are selected based on tumor stage, liver function (Child-Pugh score), and overall patient health, with a multidisciplinary approach providing the best outcomes. Curative treatments are generally reserved for early-stage disease, while systemic therapies are used for advanced stages

Methods: It is descriptive study done on the prevalence of cancer death occurred to the HCC patients (187 men and 84 women) under treatment at the Intensive Care Unit of Bertoua Regional Hospital from June to September 2025 after receiving ethical clearance and Research Authorization from Est Public Health Delegation –Cameroon. Convenience sampling was done. The analysis included chemotherapy, immunotherapy, locoregional therapies, liver transplantation and surgical resection. Data were collected using structured questionnaires, observations and analyzed using descriptive statistics and analyses

Results: Despite Sorafenib 200mggiven to the 28,04% of 271 HCC patients, 45,38% has developed liver metastasis and 25,46% are died. Any others therapiesused to treat patient such as immunotherapy, surgical resection, liver transplantation, locoregional therapies and local abblations.